Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls.
BACKGROUND
Previously, TP53 codon 72 polymorphisms have been implicated as risk factors for various cancers. A number of studies have conducted on the association of TP53 codon 72 polymorphisms with susceptibility to breast carcinoma and have yielded inconclusive results. The aim of the present study was to derive a more precise estimation of the relationship.


METHODS
We conducted a search in the Medline, EMBASE, OVID, Sciencedirect, and Chinese National Knowledge Infrastructure (CNKI) without a language limitation, covering all papers published up to Jan 2009. The associated literature was acquired through deliberate searching and selected based on the established inclusion criteria for publications.


RESULTS
A total of seventeen case-control studies, including 12226 cases and 10782 controls, met the included criteria and thus were selected. Ultimately, the relevant data were extracted and further analyzed using systematic meta-analyses. Overall, no associations of TP53 codon 72 polymorphisms with breast carcinoma were observed (for Arg/Arg vs Pro/Pro: OR = 1.20; 95%CI = 0.96-1.50; for dominant model: OR = 1.12; 95%CI = 0.96-1.32; for recessive model: OR = 1.13; 95%CI = 0.98-1.31). In the subgroup analysis by ethnicity, statistically similar results were obtained when the data were stratified as Asians, Caucasians and Africans.


CONCLUSIONS
Collectively, the results of the present study suggest that TP53 codon 72 polymorphisms might not be a low-penetrant risk factor for developing breast carcinoma.
Zhuo
Wenlei
W
Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China. zhuowenlei@yahoo.com.cn
Zhang
Yunsong
Y
Xiang
Zhaolan
Z
Cai
Lei
L
Chen
Zhengtang
Z
D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics*; D002277:Carcinoma / Q000453:epidemiology / Q000235:genetics*; D016022:Case-Control Studies; D003062:Codon / Q000737:chemistry*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D016239:MEDLINE; D011110:Polymorphism, Genetic; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D003062:Codon; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
Ann N Y Acad Sci. 2003 Dec;1010:764-70
15033824
Cancer Res. 2007 Oct 1;67(19):9584-90
17909070
Clin Cancer Res. 2005 Oct 15;11(20):7328-33
16243804
Cancer Detect Prev. 2006;30(6):523-9
17113725
Pathol Oncol Res. 2009 Sep;15(3):359-68
19048399
Psychiatry Res. 2004 Nov 30;129(1):39-44
15572183
Breast Cancer Res. 2007;9(2):R27
17428325
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2245-52
16172238
Obes Rev. 2006 Nov;7(4):333-40
17038127
Carcinogenesis. 2007 Aug;28(8):1680-6
17449902
Am J Epidemiol. 2008 Jul 15;168(2):123-37
18483125
Pharmacogenetics. 2002 Apr;12(3):269-72
11927843
Int J Cancer. 2007 Oct 1;121(7):1481-6
17546594
Acta Oncol. 2006;45(5):602-9
16864176
Clin Genet. 2006 Apr;69(4):327-36
16630166
Nat Genet. 2003 Mar;33(3):357-65
12567188
Trends Genet. 2004 Sep;20(9):439-44
15313553
Mol Cell Biochem. 2003 Oct;252(1-2):117-24
14577584
Breast Cancer Res. 2007;9(3):R34
17537232
Jpn J Clin Oncol. 2008 Nov;38(11):734-42
18820009
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):622-35
11402272
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1684-8
12496062
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):353-8
16492928
Breast Cancer. 2003;10(4):307-11
14634508
Hepatology. 1999 Mar;29(3):697-702
10051470
Cancer Lett. 2004 Jul 16;210(2):197-203
15183535
Oncol Rep. 2003 May-Jun;10(3):711-4
12684648
BMC Cancer. 2008 Jan 29;8:32
18230179
Int J Cancer. 1997 May 29;71(5):800-9
9180149
J Natl Cancer Inst. 2009 Jan 7;101(1):48-60
19116382
Tumour Biol. 2008;29(3):145-51
18612219
Carcinogenesis. 2008 Apr;29(4):754-61
18281248
Carcinogenesis. 1996 Jun;17(6):1313-6
8681448
Eur J Gynaecol Oncol. 2008;29(4):364-7
18714570
Nucleic Acids Res. 1990 Aug 25;18(16):4961
1975675
Int J Gynaecol Obstet. 2004 Jun;85(3):301-8
15145278
Mayo Clin Proc. 2006 Oct;81(10):1290-302
17036554
Cancer Genet Cytogenet. 2007 Feb;173(1):38-42
17284368
Clin Cancer Res. 2003 Oct 15;9(13):4860-4
14581358
Oncogene. 1997 Jan 30;14(4):499-506
9053847
Lung Cancer. 2009 Oct;66(1):15-21
19178978
Breast Cancer Res. 2007;9(5):R71
17945002
BMC Cancer. 2008 Dec 01;8:357
19046423
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Breast Cancer Res Treat. 2008 Feb;107(3):415-9
17453340
Oncol Rep. 2004 May;11(5):1115-20
15069555
Nature. 1998 May 21;393(6682):229-34
9607760
Mol Cell Biol Res Commun. 2000 Jun;3(6):389-92
11032762
J Cell Physiol. 2008 Aug;216(2):543-50
18330889
Int J Mol Med. 2007 Nov;20(5):731-41
17912468
J Cancer Res Clin Oncol. 2009 Mar;135(3):329-37
19009309
Breast Cancer Res Treat. 2009 May;115(1):137-44
18481169
Clin Cancer Res. 2005 Jul 15;11(14):5098-103
16033823
Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):105-12
9037561
Breast Cancer Res Treat. 2009 Sep;117(2):391-9
19145484
Cancer Lett. 2005 May 10;222(1):57-65
15837541
Fertil Steril. 2002 Jan;77(1):43-5
11779589
Am J Epidemiol. 2005 May 15;161(10):901-15
15870154
Mutagenesis. 2003 Jul;18(4):377-85
12840112
Clin Exp Med. 2005 Dec;5(4):161-8
16362795
Cancer Genet Cytogenet. 2008 Aug;185(1):20-7
18656689
Cancer. 2002 Dec 15;95(12):2571-6
12467072
Br J Cancer. 2005 Mar 28;92(6):1144-8
15756275
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 Nov;36(6):561-6
18067229
Environ Health Perspect. 1997 Jun;105 Suppl 4:919-26
9255581
Oncogene. 2006 Mar 13;25(11):1602-11
16550160
Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):11-22
14744727
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Eur J Cancer. 1999 Feb;35(2):226-30
10448264